Addressing flavivirus threats through the development of new therapies that stem from a better understanding of virus-host interactions.

Addressing flavivirus threats through the development of new therapies that stem from a better understanding of virus-host interactions.

COUNTER-ACTING THE PANDEMIC POTENTIAL OF FLAVIVIRUSES: ADDRESSING VIRUS-HOST INTERACTIONS AND DEFENCE STRATEGIES TO DESIGN NEW THERAPEUTICS AGAINST WNV AND DENV

COUNTER-ACTING THE PANDEMIC POTENTIAL OF FLAVIVIRUSES: ADDRESSING VIRUS-HOST INTERACTIONS AND DEFENCE STRATEGIES TO DESIGN NEW THERAPEUTICS AGAINST WNV AND DENV

To enhance the EU's capability in combating West Nile and Dengue virus epidemics and pandemics, and to develop effective emergency response plans.

Consortium

Problem to be solved

The spread of Flaviviruses has surged in recent decades, impacting millions and causing hundreds of thousands of deaths. Dengue virus is now endemic in over 100 countries across tropical and subtropical regions in Southeast Asia, Africa, the western Pacific, and the Americas.

Flaviviruses have a significant economic impact, costing approximately US $12 billion annually. Their epidemic potential is influenced by insect vector characteristics, poor urban planning, geographical spread due to environmental changes, and extensive global travel.

Despite the deleterious impact of flaviviral infection on human and animal health, the measures to control these viruses are still limited.

Proposed solution

InFlaMe brings together a diverse team of experts—epidemiologists, virologists, immunologists, and climate change specialists—to investigate the molecular mechanisms of DENV and WNV infections. The goal is to accelerate antiviral discovery, identify new treatment compounds, and develop effective differential diagnoses.

In InFlaMe, we will develop a comprehensive surveillance system for humans, animals, and the environment to enhance early pathogen detection and reduce disease burden.

In InFlaMe, we will develop a comprehensive surveillance system for humans, animals, and the environment to enhance early pathogen detection and reduce disease burden.

Starting

1st December 2024

Duration

48 Months

Partners

8

Countries

3

Work packages

9

Funding

2.996.312,50 €

News & Events